Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

MHC-I epitope presentation to CD8 T cells is directly dependent on peptide loading and selection during antigen processing. However, the exact molecular bases underlying peptide selection and binding by MHC-I remain largely unknown. Within the peptide-loading complex, the peptide editor tapasin is key to the selection of MHC-I-bound peptides. Here, we have determined an ensemble of crystal structures of MHC-I in complex with the peptide exchange-associated dipeptide GL, as well as the tapasin-associated scoop loop, alone or in combination with candidate epitopes. These results combined with mutation analyses allow us to propose a molecular model underlying MHC-I peptide selection by tapasin. The N termini of bound peptides most probably bind first in the N-terminal and middle region of the MHC-I peptide binding cleft, upon which the peptide C termini are tested for their capacity to dislodge the tapasin scoop loop from the F pocket of the MHC-I cleft. Our results also indicate important differences in peptide selection between different MHC-I alleles.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421438PMC
http://dx.doi.org/10.1073/pnas.1807656116DOI Listing

Publication Analysis

Top Keywords

peptide selection
12
peptide
9
peptide loading
8
complex peptide
8
scoop loop
8
mhc-i peptide
8
mhc-i
7
selection
5
successive crystal
4
crystal structure
4

Similar Publications

Retinol binding protein 4 (RBP4), the circulating carrier of retinol, complexes with transthyretin (TTR) and is a potential biomarker of cardiometabolic disease. However, RBP4 quantitation relies on immunoassays and Western blots without retinol and TTR measurement. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous absolute quantitation of circulating RBP4 and TTR is critical to establishing their biomarker potential.

View Article and Find Full Text PDF

Expression of long non-coding RNAs MALAT1, MEG3, and XIST in gestational diabetes mellitus: a cross-sectional study.

Acta Diabetol

September 2025

Department of Endocrinology & Metabolism, Medical College & Hospital, Kolkata, 88, College St. College Square, Kolkata, West Bengal, 700073, India.

Background And Aims: Gestational diabetes mellitus (GDM) is defined as glucose intolerance first identified during pregnancy that does not meet the criteria for overt diabetes. Its pathophysiology shares key features with type 2 diabetes mellitus (T2D), including insulin resistance and inflammation. Emerging evidence suggests that long non-coding RNAs (lncRNAs) are implicated in T2D.

View Article and Find Full Text PDF

Phosphole-based fluorophores are attractive dyes for bioimaging due to their relatively compact molecular structures, strong fluorescence up to the near-infrared region with large Stokes shifts, and remarkable resistance to photobleaching. Therefore, the development of efficient and chemoselective coupling methods for functionalizing phospholes is of significant interest for biomolecular labeling. Herein, we describe the synthesis of novel P-aminophospholes and their use for direct conjugation to cysteinyl peptides under mild conditions.

View Article and Find Full Text PDF

Colorectal cancer (CRC) remains a major global health burden, necessitating more effective and selective therapeutic approaches. Nanocarrier-based drug delivery systems offer significant advantages by enhancing drug accumulation in tumors, reducing off-target toxicity, and overcoming resistance mechanisms. This review provides a comprehensive overview of recent advancements in nanocarriers for CRC therapy, including passive targeting the enhanced permeability and retention (EPR) effect, and active targeting strategies that exploit specific tumor markers using ligands such as antibodies, peptides, and aptamers.

View Article and Find Full Text PDF

Background And Aims: Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options. TGF-β is a promising therapeutic target, but its dual role, as both a tumour suppressor and promoter, complicates its clinical application. While its effects on tumour cells are increasingly understood, its impact on the tumour stroma remains unclear.

View Article and Find Full Text PDF